Company Profile

IPCA LABORATORIES LTD.

NSE : IPCALABBSE : 524494ISIN CODE : INE571A01020Industry : Pharmaceuticals & DrugsHouse : Ipca Laboratories
BSE2307.00-39.25 (-1.67 % )
PREV CLOSE (Rs.) 2346.25
OPEN PRICE (Rs.) 2335.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 88849
TODAY'S LOW / HIGH (Rs.)2281.00 2397.40
52 WK LOW / HIGH (Rs.)1786.05 2767.1
NSE2309.20 -32.95 (-1.41 % )
PREV CLOSE(Rs.) 2342.15
OPEN PRICE (Rs.) 2335.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 2309.20 (270 )
VOLUME 456915
TODAY'S LOW / HIGH(Rs.) 2281.60 2400.00
52 WK LOW / HIGH (Rs.)1785.4 2766.2

Company News

Date Heading Details
20-Oct-2021 IPCA Laboratories informs about board meeting <div align="justify"><span>IPCA Laboratories has informed that the meeting of the Board of Directors of the Company is scheduled on 13/11/2021 to consider and approve the Standalone and Consolidated Unaudited financial results for the period ended September 30, 2021, Interim dividend, and sub-division of every 1 equity share of the nominal/face value of Rs 2 each into 2 equity shares of the nominal/face value of Re 1 each.</span></div><font face="sans-serif"><span><div align="justify"><br></div></span></font><div align="justify"><font face="sans-serif"><span>The above information is a part of company's filings submitted to BSE.</span></font></div><div><br></div>
01-Oct-2021 Ipca Laboratories' arm picks up additional 20% share capital of Bayshore <p align="justify">Ipca Laboratories' wholly owned subsidiary -- Ipca Pharmaceuticals, Inc., USA has acquired further 20% share capital of Bayshore Pharmaceuticals LLC (Bayshore), a New Jersey limited liability company for $1.2 million. With this acquisition, Bayshore is now wholly owned by Ipca Pharmaceuitcals, Inc.</p><p align="justify">Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in many countries and its export accounts for&nbsp;around half&nbsp;of the company's income. Worldwide the company is one of the largest suppliers of APIs and intermediates. <br></p>
01-Oct-2021 Announcement under Regulation 30 (LODR)-Acquisition Acquisition of further 20% share capital of Bayshore Pharmaceuticals LLC, New Jersey, USA by lpca Pharmaceuticals Inc.
13-Sep-2021 lpca Laboratories informs about investor meeting <p align="justify">Pursuant to Regulation 30 of the SESI (Listing Obligations and Disclosure Requirements) Regulations, 2015, lpca Laboratories has informed that the Company is participating in the virtual Annual Investor Conference organised by Motilal Oswal on Monday, 13th September, 2021 between 11.00 am to 12.00 noon. In this virtual investor meeting, only publicly available information will be shared with the Analysts/institutional investors.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
09-Aug-2021 Ipca Laboratories informs about transcript of the conference call <p align="justify">Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ipca Laboratories has informed that it enclosed the transcript of the Conference Call held on Friday, 6th August, 2021 to discuss the Company's 01 FY22 earnings and business update.</p><p align="justify">The above information is a part of company's filings submitted to BSE.</p>
05-Aug-2021 Ipca Laboratories reports 31% fall in Q1 consolidated net profit <p align="justify">Ipca Laboratories has reported results for first quarter ended June 30, 2021.<p align="justify">The company has reported a fall of 37.24% in its net profit at Rs 284.72 crore for the quarter under review as compared to Rs 453.64 crore for the same quarter in the previous year. Total income of the company decreased by 0.32% at Rs 1,492.21 crore for Q1FY22 as compared Rs 1496.93 crore for the corresponding quarter previous year.<p align="justify">On the consolidated basis, the company has reported a fall of 31.26% in its net profit attributed to the owners at Rs 306.66 crore for the quarter under review as compared to Rs 446.13 crore for the same quarter in the previous year. However, total income of the company increased by 2.61% at Rs 1,586.81 crore for Q1FY22 as compared Rs 1,546.49 crore for the corresponding quarter previous year.</p>
05-Aug-2021 Ipca Laboratories informs about 71st AGM <p align="justify">Ipca Laboratories has informed that the 71st Annual General Meeting (AGM) of the company (CIN L24239MH1949PLC007837) will be held on Thursday, 2nd September, 2021 at 3.30 pm through Video Conferencing / Other Audio-Visual Means (VC/OAVM) to transact the Ordinary business and Special Business. The detailed description regarding Ordinary business and Special Business attached.</p><p align="justify">The above information is a part of company's filings submitted to BSE.</p><p><br></p>
04-Aug-2021 Ipca Laboratories informs about annual report <p align="justify">Ipca Laboratories has informed that it has enclosed a copy of its Annual Report for the financial year ended 31st March, 2021.</p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
22-Jul-2021 Board Meeting Intimation for The Unaudited Financial Results Of The Company For The 1St Quarter Ended 30Th June, 2021 Of The Financial Year 2021-22. IPCA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2021 ,inter alia, to consider and approve the unaudited financial results of the Company for the 1st quarter ended 30th June, 2021 of the financial year 2021-22.
16-Jul-2021 Incorporation Of Section 8 Company By The Name 'Ipca Foundation' Incorporation of Section 8 Company by the name 'Ipca Foundation'